An economic evaluation of varicella vaccination in Italian adolescents (Q57515358)

8

object named as

Pierre Van Damme

0 references

Paolo Bonanni

6

object named as

Paolo Bonanni

0 references

author name string

Nancy Thiry

1

0 references

Francesco Tancredi

3

0 references

Luisa Romanò

4

0 references

Alessandro Zanetti

5

0 references

Giovanni Gabutti

The epidemiology of varicella and its complications.

7

0 references

language of work or name

English

0 references

publication date

September 2004

0 references

published in

Vaccine

0 references

volume

22

0 references

issue

27-28

0 references

page(s)

3546-3562

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Complications of varicella in a defined central European population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Varicella mortality: trends before vaccine licensure in the United States, 1970-1994

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Varicella vaccination--a critical review of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

The effectiveness of the varicella vaccine in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Postlicensure safety surveillance for varicella vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Live attenuated varicella virus vaccine. Efficacy trial in healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Varicella disease after introduction of varicella vaccine in the United States, 1995-2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Epidemiologic effects of varicella vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

The epidemiology of varicella–zoster virus infections: the influence of varicella on the prevalence of herpes zoster

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

UK and Italy have low MMR uptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Economic evaluations of varicella vaccination programmes: a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

The seroepidemiology of varicella in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

The estimation of age-related rates of infection from case notifications and serological data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Persistence of immunity to live attenuated varicella vaccine in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Epidemiology and cost analysis of varicella in Italy: results of a sentinel study in the pediatric practice. Italian Sentinel Group on Pediatric Infectious Diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

The difficult quest for data on "vanishing" vaccine-preventable infections in Europe: the case of measles in Flanders (Belgium).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Epidemiology and economic impact of varicella in immunocompetent children in Spain. A nation-wide study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

A cost benefit analysis of routine varicella vaccination in Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Childhood vaccination against chickenpox: an analysis of benefits and costs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

The cost-effectiveness of varicella vaccination in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Costs And Benefits Of Routine Varicella Vaccination In German Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

On the decision rules of cost-effectiveness analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Chickenpox outbreak in a highly vaccinated school population

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

inferred from DOI database lookup

7 January 2021

based on heuristic

The cost-effectiveness of routine childhood varicella vaccination in Germany

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Instituting a routine varicella vaccination program in Canada: an economic evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Varicella vaccine revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Economic Evaluation of Varicella Vaccination Programmes: A Review of the Literature. The Authors?? Reply

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043

Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.043